HomeCompareASPD vs ABBV

ASPD vs ABBV: Dividend Comparison 2026

ASPD yields 200.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASPD wins by $119.26M in total portfolio value
10 years
ASPD
ASPD
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full ASPD calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — ASPD vs ABBV

📍 ASPD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASPDABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASPD + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASPD pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASPD
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ASPD beats the other by $51,127,814.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASPD + ABBV for your $10,000?

ASPD: 50%ABBV: 50%
100% ABBV50/50100% ASPD
Portfolio after 10yr
$59.73M
Annual income
$30,100,911.00/yr
Blended yield
50.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ASPD
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASPD buys
0
ABBV buys
0
No recent congressional trades found for ASPD or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASPDABBV
Forward yield200.00%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$119.36M$104.7K
Annual income after 10y$60,176,096.29$25,725.73
Total dividends collected$112.49M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ASPD vs ABBV ($10,000, DRIP)

YearASPD PortfolioASPD Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$30,700$20,000.00$11,559$438.51+$19.1KASPD
2$90,232$57,383.18$13,494$640.86+$76.7KASPD
3$254,173$157,624.56$15,951$945.97+$238.2KASPD
4$686,927$414,961.74$19,152$1,413.89+$667.8KASPD
5$1,783,118$1,048,106.39$23,443$2,146.38+$1.76MASPD
6$4,450,613$2,542,677.12$29,391$3,321.96+$4.42MASPD
7$10,693,420$5,931,263.38$37,948$5,265.87+$10.66MASPD
8$24,760,608$13,318,648.86$50,795$8,596.74+$24.71MASPD
9$55,315,649$28,821,798.66$71,034$14,549.41+$55.24MASPD
10$119,363,841$60,176,096.29$104,715$25,725.73+$119.26MASPD

ASPD vs ABBV: Complete Analysis 2026

ASPDStock

Aspen Digital, Inc. is a real estate investment trust. It owns and operates St. Regis Aspen Resort. The company was founded on December 23, 2016 and is headquartered in Aspen, CO.

Full ASPD Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ASPD vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASPD vs SCHDASPD vs JEPIASPD vs OASPD vs KOASPD vs MAINASPD vs JNJASPD vs MRKASPD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.